Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 20 | 2025 | 325 | 2.930 |
Why?
|
| Hydroxyurea | 2 | 2020 | 86 | 0.690 |
Why?
|
| Recombinases | 3 | 2025 | 27 | 0.620 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2025 | 66 | 0.480 |
Why?
|
| Glioma | 4 | 2007 | 480 | 0.380 |
Why?
|
| Erythrocyte Aging | 1 | 2011 | 4 | 0.350 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2024 | 138 | 0.350 |
Why?
|
| Antisickling Agents | 1 | 2011 | 19 | 0.340 |
Why?
|
| Acetamides | 1 | 2011 | 44 | 0.330 |
Why?
|
| Hemolysis | 1 | 2011 | 103 | 0.330 |
Why?
|
| Cytapheresis | 1 | 2009 | 1 | 0.320 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 200 | 0.290 |
Why?
|
| beta-Globins | 2 | 2025 | 9 | 0.290 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 136 | 0.280 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2007 | 7 | 0.270 |
Why?
|
| Brain Stem Neoplasms | 1 | 2007 | 40 | 0.260 |
Why?
|
| Cerebral Infarction | 3 | 2014 | 46 | 0.240 |
Why?
|
| Pain | 4 | 2017 | 429 | 0.230 |
Why?
|
| Child, Preschool | 17 | 2024 | 14512 | 0.230 |
Why?
|
| Child | 23 | 2024 | 25352 | 0.230 |
Why?
|
| Alleles | 3 | 2025 | 1609 | 0.230 |
Why?
|
| Hemoglobin, Sickle | 4 | 2021 | 19 | 0.230 |
Why?
|
| Neonatal Screening | 2 | 2017 | 190 | 0.220 |
Why?
|
| Blood Transfusion | 3 | 2021 | 288 | 0.210 |
Why?
|
| Magnesium Sulfate | 1 | 2014 | 51 | 0.200 |
Why?
|
| Menorrhagia | 1 | 2024 | 81 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 1206 | 0.200 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 98 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 3723 | 0.200 |
Why?
|
| Adolescent | 18 | 2024 | 20176 | 0.200 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 131 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 34 | 0.190 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1178 | 0.180 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 176 | 0.180 |
Why?
|
| Angola | 2 | 2018 | 6 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 221 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 222 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 457 | 0.160 |
Why?
|
| Malaria | 1 | 2021 | 97 | 0.160 |
Why?
|
| Humans | 34 | 2025 | 127593 | 0.160 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 63 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 174 | 0.160 |
Why?
|
| Iron | 1 | 2022 | 300 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2010 | 121 | 0.150 |
Why?
|
| Hemoglobins | 2 | 2022 | 313 | 0.140 |
Why?
|
| Hematology | 1 | 2018 | 41 | 0.140 |
Why?
|
| Pediatrics | 2 | 2018 | 1206 | 0.140 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 75 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2010 | 285 | 0.130 |
Why?
|
| Algorithms | 1 | 2024 | 1639 | 0.130 |
Why?
|
| Blood Pressure | 2 | 2014 | 1338 | 0.130 |
Why?
|
| Paper | 1 | 2017 | 7 | 0.130 |
Why?
|
| Female | 19 | 2024 | 68816 | 0.130 |
Why?
|
| Anemia | 1 | 2021 | 341 | 0.130 |
Why?
|
| Male | 18 | 2024 | 62943 | 0.130 |
Why?
|
| Platelet Count | 2 | 2022 | 132 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2753 | 0.120 |
Why?
|
| Quality Improvement | 3 | 2024 | 684 | 0.120 |
Why?
|
| Infant | 9 | 2024 | 12842 | 0.120 |
Why?
|
| Ikaros Transcription Factor | 1 | 2015 | 29 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 294 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 318 | 0.110 |
Why?
|
| Patient Care | 2 | 2018 | 99 | 0.110 |
Why?
|
| Magnesium | 1 | 2015 | 119 | 0.110 |
Why?
|
| Stroke | 1 | 2023 | 1030 | 0.110 |
Why?
|
| Quality of Life | 3 | 2017 | 2032 | 0.110 |
Why?
|
| Length of Stay | 3 | 2015 | 1378 | 0.110 |
Why?
|
| Body Height | 1 | 2014 | 192 | 0.100 |
Why?
|
| Neoplasms | 2 | 2014 | 2852 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 3001 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8391 | 0.090 |
Why?
|
| Global Health | 1 | 2017 | 609 | 0.090 |
Why?
|
| Young Adult | 6 | 2023 | 9704 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2024 | 17111 | 0.090 |
Why?
|
| beta-Thalassemia | 1 | 2011 | 26 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2015 | 1602 | 0.090 |
Why?
|
| Prognosis | 3 | 2024 | 4804 | 0.090 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 15 | 0.090 |
Why?
|
| Acute Chest Syndrome | 1 | 2011 | 10 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 574 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1277 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 727 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 5170 | 0.080 |
Why?
|
| Hematocrit | 1 | 2011 | 110 | 0.080 |
Why?
|
| Body Weight | 1 | 2014 | 971 | 0.080 |
Why?
|
| HIV Infections | 1 | 2022 | 1954 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 736 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 291 | 0.070 |
Why?
|
| Chest Pain | 1 | 2009 | 124 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 538 | 0.070 |
Why?
|
| Brain | 1 | 2010 | 3034 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 790 | 0.070 |
Why?
|
| Risk Factors | 5 | 2024 | 10645 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2014 | 539 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 236 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2023 | 1050 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1199 | 0.060 |
Why?
|
| Syndrome | 1 | 2009 | 1140 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 1235 | 0.060 |
Why?
|
| Neurologic Examination | 1 | 2007 | 194 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 489 | 0.060 |
Why?
|
| Adult | 6 | 2024 | 30628 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 549 | 0.050 |
Why?
|
| Hospitals, Special | 1 | 2014 | 12 | 0.050 |
Why?
|
| Narcotics | 1 | 2014 | 57 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 215 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 73 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 144 | 0.050 |
Why?
|
| Point Mutation | 1 | 2024 | 335 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 14 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2023 | 81 | 0.050 |
Why?
|
| Lamivudine | 1 | 2022 | 20 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 223 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 152 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 227 | 0.050 |
Why?
|
| Hypotension | 1 | 2014 | 184 | 0.050 |
Why?
|
| Middle Aged | 5 | 2015 | 27899 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 296 | 0.040 |
Why?
|
| Informed Consent | 1 | 2014 | 338 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 335 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 788 | 0.040 |
Why?
|
| Optic Nerve Glioma | 1 | 2001 | 21 | 0.040 |
Why?
|
| Disease Management | 1 | 2024 | 545 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 312 | 0.040 |
Why?
|
| United States | 3 | 2023 | 11427 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2010 | 269 | 0.040 |
Why?
|
| Probability | 1 | 2010 | 309 | 0.040 |
Why?
|
| Aged | 3 | 2011 | 20524 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 686 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 472 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 1409 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 21 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 778 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 115 | 0.040 |
Why?
|
| Death Certificates | 1 | 1998 | 11 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 197 | 0.040 |
Why?
|
| Cytokines | 1 | 2014 | 1321 | 0.030 |
Why?
|
| Isoelectric Focusing | 1 | 2017 | 23 | 0.030 |
Why?
|
| Saponins | 1 | 2017 | 21 | 0.030 |
Why?
|
| Sulfites | 1 | 2017 | 27 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2011 | 12600 | 0.030 |
Why?
|
| Canada | 1 | 1998 | 315 | 0.030 |
Why?
|
| Texas | 2 | 2007 | 3566 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2017 | 74 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 122 | 0.030 |
Why?
|
| Sex Factors | 1 | 2001 | 1314 | 0.030 |
Why?
|
| Patient Selection | 1 | 2010 | 713 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2082 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1878 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2022 | 3336 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 315 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 382 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 314 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 252 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 61 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2015 | 177 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2014 | 41 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 3254 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 805 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 106 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 237 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 190 | 0.030 |
Why?
|
| Intelligence | 1 | 2014 | 91 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 533 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 754 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 2626 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2015 | 511 | 0.020 |
Why?
|
| Allografts | 1 | 2014 | 189 | 0.020 |
Why?
|
| Incidence | 1 | 2001 | 3265 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2014 | 219 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 535 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1008 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 77 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 2895 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 316 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 3598 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 25 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 79 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2010 | 46 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 99 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 110 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 132 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 299 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1388 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 900 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 756 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 248 | 0.020 |
Why?
|
| SEER Program | 1 | 2007 | 201 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 410 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6266 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 542 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 2111 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2004 | 20 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2004 | 25 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 138 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 989 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2004 | 96 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1311 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 3711 | 0.010 |
Why?
|
| Ependymoma | 1 | 2004 | 141 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 5944 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 689 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1485 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 1370 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 1791 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 2600 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 3273 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6173 | 0.010 |
Why?
|